Sympathetic nervous system

ADARx Pharmaceuticals Appoints Dr. Chris Storgard as Chief Medical Officer

Retrieved on: 
Tuesday, April 2, 2024

SAN DIEGO, April 02, 2024 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a clinical stage biotechnology company developing next generation RNA therapeutics, today announced the appointment of Chris Storgard, M.D., as Chief Medical Officer (CMO).

Key Points: 
  • SAN DIEGO, April 02, 2024 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a clinical stage biotechnology company developing next generation RNA therapeutics, today announced the appointment of Chris Storgard, M.D., as Chief Medical Officer (CMO).
  • As CMO, Dr. Storgard will lead Clinical Research, Clinical Operations, Biometrics, Pharmacovigilance and Medical Affairs.
  • Dr. Storgard has a BSc in biology and an MD from the University of Saskatchewan in Canada.
  • Dr. Storgard completed a fellowship in rheumatology at Scripps Clinic and Research Center in San Diego, CA.

U.S. Congressman Josh Gottheimer Champions Rare Disease Research With Sponsorship of Legislative Bill - H.Res.1039 - Advocating for Increased Funding for Charcot-Marie-Tooth Disease (CMT)

Retrieved on: 
Tuesday, April 9, 2024

The resolution underscores the urgency of addressing the challenges of individuals diagnosed with Charcot-Marie-Tooth disease (CMT) and the need for robust research funding.

Key Points: 
  • The resolution underscores the urgency of addressing the challenges of individuals diagnosed with Charcot-Marie-Tooth disease (CMT) and the need for robust research funding.
  • “By collaborating with experts and advocates, we can give everyone struggling with Charcot-Marie-Tooth Disease hope.
  • Zaken's dedication reflects the grassroots efforts of young individuals committed to making a difference in the fight against rare diseases.
  • Regrettably, despite its profound impact, federal funding for CMT research witnessed a decrease in 2022 compared to 2021.

The9 Signed a Definitive Share Purchase Agreement to Invest in GenAI LLM Digital Precision Medicine Platform for Brain Disease WM Therapeutic

Retrieved on: 
Tuesday, March 26, 2024

SHANGHAI, March 26, 2024 /PRNewswire/ -- The9 Limited (Nasdaq: NCTY) ("The9"), an established Internet company, today announced that it signed a definitive share purchase agreement (the "Agreement") with WM Therapeutic Co., Ltd. ("WM Therapeutic"), a company operating Generative AI (GenAI) large language model (LLM) multi-dimensional and multi-omics digital precision medicine platform for brain disease, to purchase an additional 21.7% shares of WM Therapeutic by cash and issuance of The9's restricted shares.

Key Points: 
  • SHANGHAI, March 26, 2024 /PRNewswire/ -- The9 Limited (Nasdaq: NCTY) ("The9"), an established Internet company, today announced that it signed a definitive share purchase agreement (the "Agreement") with WM Therapeutic Co., Ltd. ("WM Therapeutic"), a company operating Generative AI (GenAI) large language model (LLM) multi-dimensional and multi-omics digital precision medicine platform for brain disease, to purchase an additional 21.7% shares of WM Therapeutic by cash and issuance of The9's restricted shares.
  • With the signing of this Agreement, The9 will own 30% of WM Therapeutic.
  • The9 is also granted a purchase option to purchase up to 51% of the total shares of WM Therapeutic under certain conditions.
  • WM Therapeutic develops GenAI large language model brain disease screening platform and digital human personalized psychological consultant, AI precision diagnostic equipment, personalized neuromodulation treatment equipment, Generative AI large language model and AI drug clinical research platform.

Zenith Epigenetics Proudly Supports Rare Disease Day

Retrieved on: 
Thursday, February 29, 2024

ZEN-3694 Expands Development to Include Multiple Rare Oncology Indications

Key Points: 
  • Calgary, Alberta--(Newsfile Corp. - February 29, 2024) - Zenith Epigenetics Ltd. ("Zenith" or the "Company") announces its support of Rare Disease Day by highlighting our expanded development efforts of BET inhibitor ZEN-3694 for rare oncology diseases.
  • Rare Disease Day takes place every year on the last day of February, with this leap year day being the rarest of all Rare Disease Days.
  • This event is a global movement to promote equity in healthcare, and access to diagnosis and therapies for individuals living with rare diseases.
  • We are very pleased that NUT carcinoma patients receiving ZEN-3694 in clinical trial and compassionate use settings have benefitted from our drug," said Donald McCaffrey, CEO of Zenith Epigenetics.

Neuraptive Therapeutics, Inc. Announces Positive 24-Week Data for NTX-001 in the Phase 2 NEUROFUSE Study, Reinforcing Previously Announced Proof of Concept 12-Week Data

Retrieved on: 
Thursday, February 22, 2024

At the 24-week mark, NTX-001 continues to demonstrate an encouraging safety profile, with lower treatment-emergent adverse event rates than the standard of care.

Key Points: 
  • At the 24-week mark, NTX-001 continues to demonstrate an encouraging safety profile, with lower treatment-emergent adverse event rates than the standard of care.
  • The secondary endpoints, including the Numerical Pain Rating Scale, also showed statistically significant improvements, favoring NTX-001 at the 24-week timepoint.
  • Neuraptive Therapeutics, Inc. is dedicated to the innovation and development of medical products and therapeutics to repair and regenerate peripheral nerves.
  • Neuraptive Therapeutics, Inc. disclaims any obligation to update the information contained in these forward-looking statements.

CND Life Sciences Partners with Visiopharm on Novel AI-Tool to Detect and Quantify Pathological Alpha-Synuclein in Cutaneous Nerves

Retrieved on: 
Tuesday, March 5, 2024

SCOTTSDALE, Ariz.., March 5, 2024 /PRNewswire/ -- CND Life Sciences (CND), a medical technology company pioneering the development of cutaneous neurodiagnostic tests and associated biomarker services, today will unveil its NerValence pathology detection system at the AD/PD 2024 conference in Lisbon, Portugal. NerValence, developed through a strategic collaboration with precision pathology company Visiopharm, significantly enhances CND's biomarker testing services for clinical trials targeting the alpha-synuclein protein in patients with suspected Parkinson's disease, dementia with Lewy bodies, and related disorders.

Key Points: 
  • NerValence aids in the identification, tracking, and measuring the volume of alpha-synuclein in cutaneous nerves.
  • NerValence features machine learning algorithms that recognize and differentiate microscopic structures, nerves, and important disease markers that can be found in cutaneous tissue.
  • "Utilizing our novel deep learning technology to power this crucial advancement in neurodegenerative diseases represents a significant leap forward in analyzing peripheral nerves," said Michael Grunkin , Visiopharm Chief Executive Officer.
  • "Collaborating with CND Life Sciences on its deployment of NerValence will continue to be a major priority as we advance AI-driven precision pathology to enhance biopharmaceutical drug development."

We designed wormlike, limbless robots that navigate obstacle courses − they could be used for search and rescue one day

Retrieved on: 
Wednesday, February 14, 2024

These robots could come in handy in search-and-rescue situations, where they could navigate collapsed buildings to find and assist survivors.

Key Points: 
  • These robots could come in handy in search-and-rescue situations, where they could navigate collapsed buildings to find and assist survivors.
  • With slender, flexible bodies, limbless robots could readily move through confined and cluttered spaces such as debris fields, where walking or wheeled robots and human rescuers tend to fail.
  • However, even the most advanced limbless robots have not come close to moving with the agility and versatility of worms and snakes in difficult terrain.

Undulators and mechanical intelligence

  • Our team wanted to figure out a way to simplify these systems by highlighting mechanically controlled approaches to dealing with obstacles that don’t require sensors or computation.
  • Animals don’t rely solely on their neurons – brain cells and peripheral nerves – to control movement.
  • While computational systems are governed by the laws of mathematics, mechanical systems are governed by physics.
  • To achieve the same task, scientists can either design an algorithm or carefully design a physical system.
  • If you compare a diverse set of undulating organisms with the increasingly large zoo of robotic “snakes,” one difference between the robots and biological undulators stands out.


To get to the bottom of this question, our team built a new robot called MILLR, for mechanically intelligent limbless robot, inspired by the two bands of muscle on snakes and worms. MILLR has two independently controlled cables that pull each joint left and right, bilaterally.
We found this method allows the robot to spontaneously move around obstacles without having to sense its surroundings and actively change its body posture to comply to the environment.

Building a mechanically intelligent robot

  • This way, it mirrors the muscle activation methods that snakes and nematodes use, where the left and right sides take turns activating.
  • This activation mode pulls the body toward one side or another by tightening on one side, while the other side relaxes and is pulled along passively.
  • When the robot collides with an obstacle, depending on the cable tension, it selectively maintains its shape or bends under the force of the obstacle.
  • If, alternatively, the robot experienced a force that opposed the bend, it would remain rigid and push itself off the obstacle.

Testing MILLR

  • We sent MILLR through a similar course and compared the results.
  • We noticed that the worms made the same type of body movements when they collided with obstacles as MILLR did.


This work was supported by the National Science Foundation Physics of Living Systems Student Research Network, NSF-Simons Southeast Center for Mathematics and Biology, Army Research Office Grant, and the Dunn Family Professorship.

Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)

Retrieved on: 
Thursday, February 8, 2024

ATH-1105 is a next-generation, orally administered small molecule drug candidate designed to enhance the neurotrophic hepatocyte growth factor (HGF) system.

Key Points: 
  • ATH-1105 is a next-generation, orally administered small molecule drug candidate designed to enhance the neurotrophic hepatocyte growth factor (HGF) system.
  • “These data demonstrate that ATH-1105 treatment results in significant, consistent beneficial effects both in cell culture and in vivo models of ALS.
  • “There is an urgent need for new ALS treatment options, particularly those aimed at slowing or stopping neurodegeneration,” said Mark Litton, Ph.D., President and Chief Executive Officer of Athira.
  • These findings further support our plans to progress ATH-1105 into first-in-human studies in the first half of 2024.”

How much weight do you actually need to lose? It might be a lot less than you think

Retrieved on: 
Monday, February 5, 2024

But type “setting a weight loss goal” into any online search engine and you’ll likely be left with more questions than answers.

Key Points: 
  • But type “setting a weight loss goal” into any online search engine and you’ll likely be left with more questions than answers.
  • They’ll typically use a body mass index (BMI) calculator to confirm a “healthy” weight and provide a goal weight based on this range.
  • Most sales pitches will suggest you need to lose substantial amounts of weight to be healthy – making weight loss seem an impossible task.

Using BMI to define our target weight is flawed

  • So it’s no surprise we use measurements and equations to score our weight.
  • BMI classifies bodies as underweight, normal (healthy) weight, overweight or obese and can be a useful tool for weight and health screening.


fails to consider two critical factors related to body weight and health – body fat percentage and distribution
does not account for significant differences in body composition based on gender, ethnicity and age.

How does losing weight benefit our health?

  • Losing just 5–10% of our body weight – between 6 and 12kg for someone weighing 120kg – can significantly improve our health in four key ways.
  • But research shows improvements in total cholesterol, LDL cholesterol and triglyceride levels are evident with just 5% weight loss.
  • Excess weight is linked to high blood pressure in several ways, including changing how our sympathetic nervous system, blood vessels and hormones regulate our blood pressure.
  • A meta-analysis of 25 trials on the influence of weight reduction on blood pressure also found every kilo of weight loss improved blood pressure by one point.
  • Research shows just 7% weight loss reduces risk of developing type 2 diabetes by 58%.
  • In one study each kilogram of weight loss resulted in a fourfold decrease in the load exerted on the knee in each step taken during daily activities.

Focus on long-term habits

  • An analysis of 29 long-term weight-loss studies found participants regained more than half of the weight lost within two years.
  • When we lose weight, we take our body out of its comfort zone and trigger its survival response.
  • Read more:
    What's the 'weight set point', and why does it make it so hard to keep weight off?


losing weight in small manageable chunks you can sustain, specifically periods of weight loss, followed by periods of weight maintenance, and so on, until you achieve your goal weight
making gradual changes to your lifestyle to ensure you form habits that last a lifetime.
Setting a goal to reach a healthy weight can feel daunting. But it doesn’t have to be a pre-defined weight according to a “healthy” BMI range. Losing 5–10% of our body weight will result in immediate health benefits. At the Boden Group, Charles Perkins Centre, we are studying the science of obesity and running clinical trials for weight loss. You can register here to express your interest.
Dr Nick Fuller works for the University of Sydney and has received external funding for projects relating to the treatment of overweight and obesity. He is the author and founder of the Interval Weight Loss program.

Harris Poll Survey Finds People Receiving Treatment for CIDP Are Interested in Exploring More Convenient Treatment Options

Retrieved on: 
Tuesday, January 16, 2024

KING OF PRUSSIA, Pa., Jan. 16, 2024 /PRNewswire/ -- CSL Behring, a business unit of global biotechnology leader CSL, today announced survey results showing that the majority of surveyed people living with chronic inflammatory demyelinating polyneuropathy (CIDP) agree they are interested in exploring more convenient treatment options (n=98, 82%) and that administering treatment at home is extremely/very important to them (n=100, 72%). However, less than half of people surveyed said they discuss potential new treatment options or switching treatments with a physician (n=100, 47% and 43% respectively). The CSL Behring-sponsored Harris Poll survey included 100 people living with CIDP, 98 of whom were currently on treatment for their CIDP, and 100 neurologists/neuromuscular specialists who regularly see at least one patient with CIDP.

Key Points: 
  • However, less than half of people surveyed said they discuss potential new treatment options or switching treatments with a physician (n=100, 47% and 43% respectively).
  • The CSL Behring-sponsored Harris Poll survey included 100 people living with CIDP, 98 of whom were currently on treatment for their CIDP, and 100 neurologists/neuromuscular specialists who regularly see at least one patient with CIDP.
  • Additionally, less than half of patients surveyed said they are very/somewhat knowledgeable about how different CIDP treatment options work (40%) or about how different CIDP treatment options are administered (45%).
  • "We are proud to be at the forefront of delivering both effective and convenient treatment options like Hizentra, which may allow those living with CIDP more flexibility by allowing them to self-administer their treatment at home.